Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,555 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ProKidney Corporation | PROK | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.03 | -1.30% | 2.27 | 07:32:58 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.30 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 8 | 1,555 | - | 1.12 - 13.51 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:32:58 | formt | 1,000 | US$ 2.27 | USD |
ProKidney Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.18B | 235.43M | - | 0 | -35.47M | -0.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ProKidney News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PROK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.72 | 3.02 | 2.0603 | 2.39 | 899,127 | -0.45 | -16.54% |
| 1 Month | 1.58 | 3.37 | 1.4081 | 2.30 | 1,168,570 | 0.69 | 43.67% |
| 3 Months | 1.25 | 3.37 | 1.18 | 1.93 | 758,670 | 1.02 | 81.60% |
| 6 Months | 1.50 | 3.37 | 1.12 | 1.78 | 825,620 | 0.77 | 51.33% |
| 1 Year | 9.48 | 13.51 | 1.12 | 3.63 | 639,245 | -7.21 | -76.05% |
| 3 Years | 9.40 | 14.19 | 1.12 | 4.59 | 410,198 | -7.13 | -75.85% |
| 5 Years | 9.40 | 14.19 | 1.12 | 4.59 | 410,198 | -7.13 | -75.85% |
ProKidney Description
| ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. |
